3 ∆XIS Advisors

Projects

Our Work

Posts tagged Medicare
Analysis of Prescription Drug Prices in Hospitals
Analysis of Prescription Drug Prices in Hospitals

In an effort to curb skyrocketing medical debt, the Hospital Price Transparency Rule mandates that U.S. hospitals disclose their "standard charges," yet this comprehensive analysis of over 1,300 facilities reveals a stark divide between technical compliance and actual transparency. While 93% of hospitals have adopted the required file formats, only 62% provide usable pricing data for high-expenditure medications, such as those used for cancer and multiple sclerosis treatment. This significant data gap — compounded by the discovery that prices for the same drug can fluctuate ten-fold or more depending on the specific payer contract — suggests that while the "information barriers" are beginning to crack, many hospitals are opting for "in-form" compliance rather than providing the genuine clarity needed to empower patients and foster a truly competitive market. This report provides an in-depth look at both the progress and lack of progress in arming consumers with the tools necessary to make informed decisions, as well as the stark differences and disconnect that hospital prices have from drug to drug, payer to payer, and hospital to hospital.

Read More
3 Axis AdvisorsMedicare, Hospitals, 340B, Keytruda, Ocrevus, Tysabri, Darzalex Faspro, Opdivo
Comparing International Drug Prices to Prices in the United States
Comparing International Drug Prices to Prices in the United States

Many studies have examined the pricing differences in prescription drugs between the United States and other countries around the globe. Those studies have consistently found that the U.S. is paying more for prescription medications than our global peers.

For years, policy proposals at both the federal and state levels have sought to address the affordability of prescription medications in the U.S. by accessing international prices.

At times, these proposals have been to benchmark U.S. drug prices to international prices. Other proposals have sought to directly source the medications internationally at their lower cost rather than through using the existing U.S. distribution system. Overwhelmingly, studies of international prices have resulted in aggregate figures of savings but have been sparse on which drug prices are actually producing the savings.

In this report, we undertook a study of international drug prices that sought to not only confirm that international prices remain cheaper than the prices incurred by prescription drug programs in the United States (like Medicare), but to provide transparency around price differentials on a product-to-product basis.

Read More
3 Axis AdvisorsDrug Pricing, International drug prices, rebates, Medicare, Australia, Canada, WAC